Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
astrazeneca
4
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
biotech
boston top stories
clinical trials
deals
eli lilly
fda
startups
allergan
alnylam pharmaceuticals
biogen
cancer
What
bio
4
×
roundup
acquisitions
ceo
daniel
gilead
o’day
sciences
alzheimer’s
announced
august
biggest
biotech
build
busy
buy
collabs
company’s
congress
covid
days
deal
debut
decisions
democrats
devices
divided
drug
drugs
dyne’s
elections
fallout
fda
gilead’s
help
introduce
ipo
legacy
losses
medicines
Language
unset
Current search:
astrazeneca
×
novartis
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel